文献速递乳腺MR

基于MRI的肿瘤内异质性量化预测乳腺癌新辅助化疗治疗反应

MRI-based Quantification of Intratumoral Heterogeneity for Predicting Treatment Response to Neoadjuvant Chemotherapy in Breast Cancer.
PubMed 文献 · Radiology · 2023-01-01

该研究在多个中心回顾性采集乳腺癌患者新辅助化疗前MRI,提取常规影像组学特征和肿瘤内生态多样性特征生成影像组学评分和肿瘤内异质性指数,结合临床病理变量构建预测模型,训练集AUC为0.90,三个外部测试集AUC为0.83-0.87。

要点

  • 肿瘤内异质性指数和新辅助化疗前MRI影像组学评分与新辅助化疗后病理完全缓解独立相关。
  • 联合模型在训练集预测病理完全缓解的AUC为0.90,外部测试集AUC为0.83-0.87。
  • 分子亚型、肿瘤内异质性指数和常规影像组学评分均是病理完全缓解的独立预测因素。

核心结论

  • 联合基于治疗前MRI影像特征量化的肿瘤内异质性指数、常规影像组学评分和临床病理变量的模型,在预测乳腺癌患者新辅助化疗后病理完全缓解方面表现出良好性能。

研究设计与样本

  • 多中心回顾性研究,训练数据集来自中心A和B的335例患者(中位年龄48岁,IQR 42-54岁),三个外部测试数据集分别纳入590、280和384例患者(中位年龄48岁,IQR 41-55岁),采集时间为2000年1月至2020年9月。

诊断标准与关键数值

  • 分子亚型与病理完全缓解的OR范围为4.76-8.39(95%CI:1.79,24.21;所有P<.01);肿瘤内异质性指数OR为30.05(95%CI:8.43,122.64;P<.001);常规影像组学评分OR为29.90(95%CI:12.04,81.70;P<.001);联合模型训练集AUC为0.90,外部测试集AUC范围为0.83-0.87。

临床应用与阅片要点

  • 作者认为,联合治疗前MRI影像特征量化的肿瘤内异质性指数、常规影像组学评分和临床病理变量的模型可能有助于预测乳腺癌新辅助化疗后的病理完全缓解。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

英文原文(摘要)· 点击展开

Background Breast cancer is highly heterogeneous, resulting in different treatment responses to neoadjuvant chemotherapy (NAC) among patients. A noninvasive quantitative measure of intratumoral heterogeneity (ITH) may be valuable for predicting treatment response. Purpose To develop a quantitative measure of ITH on pretreatment MRI scans and test its performance for predicting pathologic complete response (pCR) after NAC in patients with breast cancer. Materials and Methods Pretreatment MRI scans were retrospectively acquired in patients with breast cancer who received NAC followed by surgery at multiple centers from January 2000 to September 2020. Conventional radiomics (hereafter, C-radiomics) and intratumoral ecological diversity features were extracted from the MRI scans, and output probabilities of imaging-based decision tree models were used to generate a C-radiomics score and ITH index. Multivariable logistic regression analysis was used to identify variables associated with pCR, and significant variables, including clinicopathologic variables, C-radiomics score, and ITH index, were combined into a predictive model for which performance was assessed using the area under the receiver operating characteristic curve (AUC). Results The training data set was comprised of 335 patients (median age, 48 years [IQR, 42-54 years]) from centers A and B, and 590, 280, and 384 patients (median age, 48 years [IQR, 41-55 years]) were included in the three external test data sets. Molecular subtype (odds ratio [OR] range, 4.76-8.39 [95% CI: 1.79, 24.21]; all P < .01), ITH index (OR, 30.05 [95% CI: 8.43, 122.64]; P < .001), and C-radiomics score (OR, 29.90 [95% CI: 12.04, 81.70]; P < .001) were independently associated with the odds of achieving pCR. The combined model showed good performance for predicting pCR to NAC in the training data set (AUC, 0.90) and external test data sets (AUC range, 0.83-0.87). Conclusion A model that combined an index created from pretreatment MRI-based imaging features quantitating ITH, C-radiomics score, and clinicopathologic variables showed good performance for predicting pCR to NAC in patients with breast cancer. © RSNA, 2023 Supplemental material is available for this article. See also the editorial by Rauch in this issue.

来源:Radiology,查看原文。版权归原作者所有。

引用

  1. Shi Z, Huang X, Cheng Z, et al. MRI-based Quantification of Intratumoral Heterogeneity for Predicting Treatment Response to Neoadjuvant Chemotherapy in Breast Cancer. Radiology. 2023. PMID: 37432083. doi:10.1148/radiol.222830

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。